Loading ...
Sorry, an error occurred while loading the content.

Doubts Over Smallpox Vaccines Emerge

Expand Messages
  • NHNE
    NHNE News List Current Members: 656 Subscribe/unsubscribe/archive info at the bottom of this message. ... DOUBTS OVER UK SMALLPOX VACCINE DISMISSED By Debora
    Message 1 of 1 , Jul 30, 2002
      NHNE News List
      Current Members: 656
      Subscribe/unsubscribe/archive info at the bottom of this message.


      By Debora MacKenzie
      New Scientist
      Tuesday, July 30, 2002

      The smallpox vaccines ordered by the UK and the US are likely to be equally
      effective -- or, possibly, they may be equally ineffective.

      Reports that the strain of smallpox vaccine now being stockpiled by the UK
      will not work, while the US stockpiled vaccine will, are wrong, according to
      smallpox experts.

      But New Scientist can also reveal that neither is certain to work. This is
      because the old tried-and-tested vaccines, which eradicated smallpox, were
      made on the skin of live animals and the new ones will not be.

      The US currently has a stockpile of 165 million doses of the old-style
      smallpox vaccine. But because of fears following the events of September 11
      that terrorists may possess smallpox, the US decided to order an extra 55
      million doses of new vaccine a year from the UK-based firm Acambis.

      In April 2001, the UK followed suit by ordering an undisclosed number of
      doses of new vaccine from the British firm PowderJect, to add to its three
      million dose stockpile of old vaccine.

      Weaponised strain

      The UK contract had already been criticised by opponents of the UK's
      governing Labour Party, because PowderJect CEO Paul Drayson has donated
      money to Labour. But on Tuesday, allegations surfaced in the UK press that
      the choice was not even medically warranted, as the UK vaccine will be
      derived from the Lister strain, while the US will use a strain named after
      the New York City Board of Health.

      The charge is that Lister will not protect against an especially virulent
      strain of smallpox, India-1967, which was weaponised by the tonne under the
      old Soviet bioweapons programme. It is feared that this strain is most
      likely to have fallen into unfriendly hands.

      The NYCBH strain probably does work against India-1967, as a Soviet
      derivative of it was widely used during the smallpox eradication campaign in

      "But Lister vaccines were used very widely in India, and they worked" says
      Ian Simpson of the World Health Organization. In fact, Lister was the most
      widely used smallpox vaccine in the world, according to the WHO, which
      supplied the strain to vaccine manufacturers. The WHO advised either strain
      could be used in the eradication programme.

      Scraping skin

      But all that may have little to do with the vaccines being made now. The old
      vaccines were made by infecting animals with the Vaccinia virus, a
      smallpox-relative, and then scraping infected material off pustules on their

      That is no longer an acceptable production method, because of the
      possibility of contamination with other pathogens. Both Acambis and
      PowerJect will be making their vaccines under sterile conditions in large
      cultures of cells.

      However, the European Agency for the Evaluation of Medicinal Products
      (EMEA), the EU's governing body for pharmaceuticals, warns in a June report:
      "There is little or no experience of the effectiveness of cell culture grown
      vaccines against smallpox."

      It notes that production using tissue cultures would select for strains of
      the virus that thrive in those cells, meaning that the final strain emerging
      from intensive cell culture may bear little comparison to its parents.

      Safety tests

      The EMEA warns that the effect of this on the efficacy and safety of the
      vaccine needs to be studied. The effect might be so large compared to
      differences in the parent strains that the EMEA felt it could not recommend
      either Lister or NYCBH as the parent strain of choice.

      Simpson cautions that "there is no reason to think tissue-culture produced
      vaccines will necessarily be less effective than the old vaccines". It is
      simply not known.

      Safety studies are underway for the Acambis vaccine, but there is no way to
      test either vaccine's effectiveness at protecting humans -- smallpox has
      been eradicated. EMEA recommends tests in animals using related pox
      diseases, and measuring antibodies after vaccinating humans, but it is not
      known what antibody profile means safety.


      NHNE News List:

      To subscribe, send a message to:

      To unsubscribe, send a message to:

      To review current posts:

      Published by NewHeavenNewEarth (NHNE)
      eMail: nhne@...
      NHNE Website: http://www.nhne.com/
      Phone: (928) 282-6120
      Fax: (815) 346-1492

      Appreciate what we are doing?
      You can say so with a tax-deductible donation:

      P.O. Box 2242
      Sedona, AZ 86339
    Your message has been successfully submitted and would be delivered to recipients shortly.